Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as teriparatid
PTH134 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| PTH134 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Forsteo | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Cross-over treatment with increasing doses of PTH134, placebo and active comparator. |
| Name | Type | Description |
|---|---|---|
| PTH134 | DRUG | - |
| Placebo | DRUG | - |
| Forsteo | DRUG | - |
Inclusion Criteria: * Post-menopausal women osteoporotic/osteopenic with an additional risk factor 45 to 80 years old Exclusion Criteria: * Use of estrogen or hormone replacement therapy * Use of parathormone or parathormone fragments, calcitonin, aluminum supplements, within 12 months prior to f...
PTH134 is an investigational small molecule being developed for postmenopausal osteoporosis, a condition that weakens bones in women after menopause. It is in Phase 1 clinical development and has not been approved by the FDA.
PTH134 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is currently in Phase 1 clinical trials.
PTH134 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and the drug remains investigational, meaning it has not received regulatory approval.
PTH134 has been studied in two completed Phase 1 trials. One trial, NCT00676312, enrolled 32 healthy postmenopausal subjects in Switzerland. Another trial, NCT01224717, enrolled 104 postmenopausal women in Denmark and Germany.
PTH134 is the sole name used for this investigational drug in clinical trials. No alternative names have been reported for this compound.